Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC)

Date

07 Oct 2016

Session

Breast cancer, early

Presenters

Sara Hurvitz

Citation

Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435

Authors

S. Hurvitz1, M.F. Abad2, R. Rostorfer3, D. Chan4, D. Egle5, C. Huang6, S. Barriga7, T.M. Costigan8, C.W. Caldwell9, J.M. Schilder10, M.F. Press11, D. Slamon12, M. Martin13

Author affiliations

  • 1 Hematology/oncology, UCLA Medical Center, Santa Monica, 90404 - Santa Monica/US
  • 2 Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 3 Medical Oncology And Hematology, UF Health Cancer Center - Orlando Health, Orlando/US
  • 4 Cancer Care Associates, University of California, Los Angeles, Redondo Beach/US
  • 5 Gynäkologie Und Geburtshilfe, Universitätsklinik Innsbruck, Innsbruck/AT
  • 6 Department Of Surgery, National Taiwan University Hospital, Taipei/TW
  • 7 Global Medical Development Oncology, Eli Lilly and Company, Madrid/ES
  • 8 Global Statistics Oncology, Eli Lilly and Company, Indianapolis/US
  • 9 Tailored Therapeutics Oncology, Eli Lilly and Company, Indianapolis/US
  • 10 Us Medical Affairs & Late Phase Product Development, Eli Lilly and Company, Indianapolis/US
  • 11 Department Of Pathology, University of Southern California, Los Angeles/US
  • 12 Hematology/oncology, UCLA Medical Center, Santa Monica, Santa Monica/US
  • 13 Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
More

Resources

Background

Abemaciclib is a potent, oral small-molecule inhibitor of CDK4 and 6 administered on a continuous dosing schedule, with evidence of single-agent antitumor activity and an acceptable safety profile when combined with an aromatase inhibitor in patients (pts) with refractory HR+ metastatic BC.

Methods

This phase II study (NCT02441946) compared the biologic activity of neoadjuvant abemaciclib plus anastrozole (ANZ; combo), abemaciclib monotherapy, and ANZ monotherapy in women with untreated early-stage invasive BC. All pts were randomized (1:1:1) for the first 2 weeks and then received combo therapy during the subsequent 14 weeks. Abemaciclib was administered 150 mg orally (PO) every 12 hours, and ANZ was administered 1 mg PO daily. Loperamide was administered as primary prophylaxis with each abemaciclib dose. The primary objective was the change in tissue Ki67 from baseline to week 2. Additional objectives included safety; clinical, radiologic, and pathological response; and changes in proliferation-associated genes (PAGs).

Results

At the pre-specified 9-month interim analysis, data were available for safety (173 pts), Ki67 (64 pts), and PAGs (51 pts). Reduction in Ki67 geometric mean percent change from baseline was significantly greater (one-sided P < 0.001) with combo (-93.5%; n = 23) and abemaciclib (-93.1%; n = 19) than ANZ therapy (-71.0%; n = 22). There were a greater number of Ki67 responders (pts with Ki67 1 post baseline assessment.

Conclusions

Abemaciclib therapies reduced Ki67 more than ANZ alone. No new safety concerns were identified and diarrhea was less frequent and severe due to loperamide prophylaxis.

Clinical trial identification

NCT02441946

Legal entity responsible for the study

Eli Lilly and Company

Funding

Eli Lilly and Company

Disclosure

S. Hurvitz: Amgen, Bayer, Boehringer Ingelheim, Genentech, GSK, Lilly, Novartis, Pfizer, Roche, Biomarin, Merrimack, OBI Pharma, PUMA, Dignitana, Medivation. C-S. Huang: Lilly, Roche, Genentech, Amgen, Novartis, OBI, Boehringer Ingelheim, BioMarin, AstraZeneca, Pfizer, Abbvie. S. Barriga, J.M. Schilder: Employed by Eli Lilly and Co. T.M. Costigan: Employed by and owns stock in Eli Lilly and Co. C.W. Caldwell: Employed by Eli Lilly and Company and a stock shareholder in the company. M.F. Press: Other from Eli Lilly and Company, during the conduct of the study; personal fees and other from Cepheid, other from Pfizer, outside the submitted work. M. Martin: Novartis, Roche, Celgene, AstraZeneca. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings